<DOC>
	<DOCNO>NCT02441933</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , phase III study compare anthracyclines follow taxane anthracyclines follow taxane plus carboplatin ( neo ) adjuvant therapy patient triple-negative breast cancer . Patients stage II/III operable triple-negative breast cancer eligible . Patients need adjuvant chemotherapy breast surgery well patient need neoadjuvant chemotherapy TNBC eligible .</brief_summary>
	<brief_title>Carboplatin EARLY Triple Negative Breast Cancer Trial ( PEARLY Trial )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Female patient &gt; 18 year age 2 . ECOG 0 1 3 . The tumor must invasive carcinoma breast histologic examination 4 . The tumor must determine HER2negative , follow : IHC 0 1+ ; IHC 2+ ISH nonamplified , ratio &lt; 2.0 , report , average HER2 gene copy number &lt; 6 signals/cell ; ISH nonamplified without IHC 5 . The tumor must determine ER PRnegative , assess current ASCO/CAP guideline . 6 . All follow stag criterion ( AJCC 7th edition ) must meet : Lymph nodepositive disease : cytologically positive neoadjuvant group* pathologically positive adjuvant group If lymph node cytologically pathologically negative , tumor size must &gt; 2.0 cm ( * In neoadjuvant group , evidence suspicious axillary lymph node baseline image study physical examination , FNA core biopsy require confirm nodal status ) 7 . The patient must undergo either mastectomy lumpectomy adjuvant group 8 . The patient must complete one nodal surgery procedure list adjuvant group : Sentinel lymph node biopsy ( SLNB ) alone : V If pathologic nodal stag base SLNB pN0 V If pathologic nodal stag base SLNB 1 2 positive node , primary tumor must T1 T2 pathologic evaluation lumpectomy nodal involvement must limit 1 2 positive node SLNB follow removal additional nonsentinel LNs SLN positive ; Axillary lymphadenectomy without SLNB ( In neoadjuvant group , baseline LN NAB core biopsy positive , ALND perform ) 9 ) LVEF assessment echocardiography MUGA scan must &gt; 50 % , regardless cardiac image facility 's low limit normal 10 ) The patient must adequate hepatic , renal , bone marrow function ; Bone marrow function Hb : ≥ 10.0 g/dL ANC : ≥ 1,500/µL Platelet count : ≥ 10 × 10⁴/µL Renal function Creatinine : ≤ 1.5 × UNL Creatine clearance ( Ccr ) &gt; 50 ml/min Cockcroft formula Hepatic function Total Bilirubin : ≤ 1.5 × UNL AST/ALT : ≤ 2.5 × UNL 10 ) Ability willingness comply study visit , treatment , test , protocol , per investigator 's judgment 1 . Any prior systemic treatment primary invasive breast cancer 2. cT4 pT4 tumor include inflammatory breast cancer 3 . Occult breast cancer 4 . Evidence metastatic breast cancer 5 . Patients second primary cancer ; EXCEPTIONS : adequately treat nonmelanoma skin cancer , curatively treated situ cancer cervix , DCIS breast , thyroid cancer size &lt; 2 cm ( papillary , follicular , medullary type ) , solid tumor curatively treat evidence disease &gt; 5 year prior randomization . 6 . Simultaneous bilateral breast cancer 7 . Patients consider poor medical risk due serious , uncontrolled medical disorder uncontrolled infection . 8 . Pregnant breastfeeding woman</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>